^
Association details:
| Biomarker: | AR splice variant 7 |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Nubeqa (darolutamide) (Androgen receptor inhibitor) + dordaviprone (ONC201) (AKT inhibitor, ERK inhibitor, DRD2 antagonist, ClpP agonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 1836: ONC201 shows synergistic effect with the androgen receptor AR-inhibitor darotulamide in prostate cancer models
Published date:
05/15/2020
Excerpt:
...human PC cell lines (LNCAP [castration sensitive, AR wild-type], 22Rv1 [castration-resistant cell line that expresses AR splice variant AR-V7]...Combination of ONC201 with DARO demonstrated synergy in enzalutamide resistant 22Rv1 cells expressing AR-V7 with marked reduction of nuclear localization of AR.
DOI:
10.1158/1538-7445.AM2020-1836
